Home > Insider Trading > Filing (0001640455-21-000018)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640455	Jounce Therapeutics Inc.	JNCE	Biological Products, (No Disgnostic Substances) (2836)	454870634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1693456	Elizabeth Trehu	C/O Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge MA 02139	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-20	6,500	$4.02	77,835	No	4	M	Direct
Common Stock	Disposition	2021-01-20	6,500	$12.01	71,335	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-20	6,500	$0.00	6,500	$4.02

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,050		2025-12-08	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 6,500 shares sold in the price range of $12.00 to $12.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option shares vest and become exercisable in 16 quarterly installments from December 9, 2015.